Last mentioned: Mar 22, 2026
Enphase Energy Filing
Pomerantz LLP files a separate class action against Enphase Energy alleging securities fraud.
Secondary Nektar Notice
A follow-up announcement clarifies the class period and lead plaintiff deadline for Nektar investors.
Nektar Litigation Announced
Pomerantz LLP announces the first class action filing against Nektar Therapeutics.
Pomerantz LLP has initiated class action litigation against Nektar Therapeutics and Enphase Energy, alleging securities fraud and misleading statements. These filings highlight a growing trend of legal scrutiny in the biotech and renewable energy sectors as companies navigate volatile market conditions and regulatory shifts.
This page surfaces every story mentioning Nektar Therapeutics across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Nektar Therapeutics was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |